Friedrich Graf Finckenstein
MD, PhD
Senior Vice President of Clinical Development
👥Biography 个人简介
Dr. Friedrich Graf Finckenstein led clinical development at Iovance Biotherapeutics guiding lifileucel (Amtagvi) from clinical trials to the first-ever FDA approval of a TIL product for metastatic melanoma in February 2024. His work encompassed the design of the pivotal C-144-01 trial, regulatory submissions, and the scale-up of GMP-compliant TIL manufacturing processes necessary for commercial delivery of autologous TIL therapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Friedrich Graf Finckenstein 的研究动态
Follow Friedrich Graf Finckenstein's research updates
留下邮箱，当我们发布与 Friedrich Graf Finckenstein（Iovance Biotherapeutics）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment